Ductal Lavage Identifies Patients for Chemoprevention

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 10
Volume 11
Issue 10

ORLANDO-The routine use of ductal lavage in a high-risk breast surgical oncology practice will identify many patients who may benefit substantially from chemoprevention with tamoxifen (Nolvadex), and may detect rare contralateral breast cancers missed by traditional methods, according to a report at the 38th Annual Meeting of the American Society of Clinical Oncology (abstract 193).

ORLANDO—The routine use of ductal lavage in a high-risk breast surgical oncology practice will identify many patients who may benefit substantially from chemoprevention with tamoxifen (Nolvadex), and may detect rare contralateral breast cancers missed by traditional methods, according to a report at the 38th Annual Meeting of the American Society of Clinical Oncology (abstract 193).

William C. Dooley, MD, professor of surgery and medical director of the Institute for Breast Health at the University of Oklahoma Health Sciences Center, reported on 77 women who underwent intraoperative ductal lavage. The study included 68 patients undergoing surgery for stage 0-II primary breast cancer; 5 patients with elevated breast cancer risk by the Gail model who underwent microductectomy for pathologic nipple discharge; and 4 patients who underwent re-excision of core-biopsy-proven atypical ductal or lobular hyperplasia.

All patients had at least one fluid-producing duct in the normal contralateral breast, which was successfully cannulated for ductal lavage in the operating room at the time of the surgical procedure. Cytologic diagnoses from the contralateral procedure revealed 19 patients (25%) with atypia, 16 (21%) with a hypocellular specimen, and 42 (55%) with benign cells.

In 15 patients with the finding of contralateral atypia—78% of all patients with atypia and 19% of all 77 patients—this information changed the management of the patient’s breast disease. This was usually the addition of tamoxifen as a chemo-preventive strategy where it would not have been prescribed without the information from the contralateral breast, Dr. Dooley reported.

In one case, the finding of atypia led to the diagnosis of an occult malignancy that was clinically and radiologically unsuspected.

The study adds to data from a previous larger multicenter study in which these authors participated. In that study, ductal lavage in high-risk women revealed abnormal cells in 93 of 383 women (24%). The abnormal cytology fell into the following categories: 17% mildly atypical, 6% markedly atypical, and 0.5% malignant.

Ductal lavage resulted in the collection of significantly more ductal epithelial cells than did the traditional collection method of nipple aspiration with a manual suction cup. The rate of adequate specimen collection and the diagnostic sensitivity were significantly higher with ductal lavage; fluid-yielding ducts were identified in 84% of subjects; and the concordance with the initial independent cytologic diagnosis was 89%.

The procedure is safe and well tolerated, and is now recommended by these authors for patients at high risk in a surgical oncology practice. 

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content